Poison pill: diluting the acquirer's stake and the limits of the defence in Russia

A poison pill is a shareholder right written in advance that switches on automatically as soon as a hostile acquirer crosses an ownership threshold set in the company's corporate documents, making any further buying many times more expensive. The mechanics are simple: every holder except the acquirer itself gains the ability to buy additional shares at a discount or to convert existing shares at an enhanced ratio. The number of shares outstanding rises, the raider's stake is diluted, and the money it has already put in loses value. The pill does not legally prohibit a takeover — it strips the takeover of economic sense until the acquirer reaches an agreement with the board of directors, which holds the right to redeem the pill.

Why the pill is not a defence but forced negotiation

The key element of the structure is not dilution but the right of redemption. The board holds the switch: if the acquirer's offer is deemed acceptable, the pill is removed and the deal proceeds in the ordinary way. That is why a working pill almost never goes off — it exists precisely so that it is never used. Its real effect is that the acquirer cannot build control through open-market purchases and has to come to the board, and in those negotiations the board bargains for a premium, a role in management or terms for minority shareholders.

Hence the central conflict of interest surrounding the device. For management, the pill is a tool for keeping its position, and corporate governance research consistently shows that overly rigid defensive provisions lower the market's valuation of a company: investors discount the probability that an offer favourable to them will be rejected. For shareholders, the same device can mean a higher final buyout price. Which effect prevails depends on who actually controls the board.

Varieties: flip-in, flip-over and the debt pill

The classification inherited from American practice distinguishes the flip-in, where the rights are exercised in shares of the target itself, from the flip-over, where the right converts into shares of the acquiring company once the merger is completed, poisoning the combined entity. A separate category is the "dead hand": such a pill is drafted so that only the sitting board can redeem it, not the board the acquirer would install after winning a proxy fight. There is also a "shadow" variety — the device is not adopted in advance but is prepared and can be put in place by the board within days of a threat emerging.

A related structure lives in debt. A change-of-control covenant gives bondholders the right to demand early redemption if the controlling stake passes into other hands. For the acquirer, this means that along with the company it is buying debt that is immediately called for repayment, and the deal price has to be calculated including that amount. Such terms appear regularly in Russian issue documents — they should be looked for not in the charter but in the prospectus of the specific issue in the bonds section, where the grounds for early redemption are described.

What of this applies under Russian law

A plain caveat is needed here: the pill in its American form can hardly be reproduced in Russia, and the reason lies not in deal culture but in how joint-stock company law is built.

First, a company cannot issue shares on the decision of the board alone, in an arbitrary volume and at an understated price, to a selected group of persons. An additional share issue requires a corporate decision taken in the prescribed manner, the placement price is set by the board on the basis of market value, and existing shareholders — including the acquirer itself — have a pre-emptive right to buy. A tool that is supposed to strike selectively strikes everyone equally here.

Second, the law on joint-stock companies itself contains protection for minority shareholders rather than for management: once an ownership threshold is crossed, the acquirer is obliged to send the other shareholders a mandatory buyout offer (Article 84.2). This rule addresses the same problem of "creeping acquisition" for which the pill was devised in another market, but it resolves it in favour of the sellers rather than the incumbent board.

Third, a staggered board — the usual companion of the pill abroad — is impossible in Russia: the board is elected in full at every annual meeting by cumulative voting. An acquirer with a large stake gets its representatives in at once rather than waiting several cycles.

In practice, takeover defence in Russia is built differently: through the ownership structure and shareholder agreements, through cross-holdings and indirect ownership, through placing key assets at the level of subsidiaries, through debt covenants, and through the special rights of the state in certain companies, which have nothing to do with a corporate poison pill even though the press sometimes calls them that.

Where investors should look

Signs of defensive structures are not published as a separate line item — they have to be pieced together. Meeting agendas and corporate action notices can be found in the corporate events calendar; charter amendments, approvals of major transactions and decisions on additional share issues all pass through it. The ownership structure and related-party notes are disclosed in the issuer's reports. Announcements of stake-building, a mandatory offer being made or a transaction being challenged run in the news feed, while the security's profile and its free-float volume are in the stocks section. Definitions of the terms that come up in these documents are collected in the glossary.

For a minority shareholder, the conclusion comes down to telling two things apart: a defensive structure that raises the price of a future buyout and a defensive structure that shuts off the very possibility of a buyout are opposites, even when their descriptions look alike. The difference shows in who holds the right of redemption and what limits that right.